{"id":3736,"date":"2023-11-06T19:40:25","date_gmt":"2023-11-06T19:40:25","guid":{"rendered":"https:\/\/cornellilj.org\/?p=3736"},"modified":"2023-11-06T19:40:25","modified_gmt":"2023-11-06T19:40:25","slug":"avoiding-the-trips-trap-a-path-to-domestic-disclosure-of-clinical-drug-data-consistent-with-international-norms-vol-54","status":"publish","type":"post","link":"https:\/\/publications.lawschool.cornell.edu\/cilj\/2023\/11\/06\/avoiding-the-trips-trap-a-path-to-domestic-disclosure-of-clinical-drug-data-consistent-with-international-norms-vol-54\/","title":{"rendered":"Avoiding the TRIPS Trap: A Path to Domestic Disclosure of Clinical Drug Data Consistent with International Norms, Vol. 54"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"633\" src=\"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-content\/uploads\/2023\/11\/myriam-zilles-KltoLK6Mk-g-unsplash-1-1024x633.jpg\" alt=\"\" class=\"wp-image-3812\" srcset=\"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-content\/uploads\/sites\/7\/2023\/11\/myriam-zilles-KltoLK6Mk-g-unsplash-1-1024x633.jpg 1024w, https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-content\/uploads\/sites\/7\/2023\/11\/myriam-zilles-KltoLK6Mk-g-unsplash-1-300x185.jpg 300w, https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-content\/uploads\/sites\/7\/2023\/11\/myriam-zilles-KltoLK6Mk-g-unsplash-1-768x474.jpg 768w, https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-content\/uploads\/sites\/7\/2023\/11\/myriam-zilles-KltoLK6Mk-g-unsplash-1-1536x949.jpg 1536w, https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-content\/uploads\/sites\/7\/2023\/11\/myriam-zilles-KltoLK6Mk-g-unsplash-1.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Should doctors, patients, and policymakers have complete information about new drugs?  Complete transparency may seem like the obvious answer.  But the reality is that available information is often <em>incomplete<\/em>. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Should doctors, patients, and policymakers have complete information about new drugs? Complete transparency may seem like the obvious answer. But the reality is that available information is often incomplete.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[13,22,32],"tags":[],"class_list":["post-3736","post","type-post","status-publish","format-standard","hentry","category-articles-2","category-print-archive","category-volume-54-issue-4"],"acf":[],"_links":{"self":[{"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/posts\/3736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/comments?post=3736"}],"version-history":[{"count":0,"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/posts\/3736\/revisions"}],"wp:attachment":[{"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/media?parent=3736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/categories?post=3736"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/publications.lawschool.cornell.edu\/cilj\/wp-json\/wp\/v2\/tags?post=3736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}